Close Menu

NEW YORK (GenomeWeb) – The Clinical Pharmacogenetics Implementation Consortium hopes to issue guidelines for genes that the expert body has determined lack evidence and shouldn't be used to guide treatment decisions but that companies nonetheless have incorporated in testing and are heavily marketing.

At a meeting of the consortium earlier this month in Memphis, Tennessee, CPIC Co-chair Mary Relling enumerated a long list of things the group has set its sights on achieving, including issuing "guidelines for non-actionable but heavily marketed genes."

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.